Article
Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Nouvelle revue francaise d'hematologie - 1 Jan 1990
Bosly A, Brice P, Humblet Y, Doyen C, Faille A, Chatelain B, Franks C, Gisselbrecht C, Symann M
Abstract excerpt
Recipients of autologous BMT demonstrate clinically significant immune deficiency, particularly involving the T lymphocytes. While quantitatively the immune system generally returns to normal during the first 3 months, there is a prolonged delay in the recovery of qualitative immune functions. T...
Topics
- Bone Marrow Transplantation
- Combined Modality Therapy
- Humans
- Interleukin-2
- Neoplasms
- Phenotype
- Recombinant Proteins
- T-Lymphocytes
- Transplantation, Autologous